Forecast

There is no analyst data available for this company.

News Go to news feed

Mainz Biomed to be renamed Quantum Cyber and appoints Robert P. Liscouski as chairman

Mainz Biomed announces a strategic reorientation: the company will change its name to Quantum Cyber and will use the NASDAQ ticker symbol QUCY starting Thursday. Robert P. Liscouski has been appointed chairman of the board; the measures are to take effect at an extraordinary general meeting in April. The reorientation follows ongoing financial difficulties, with a share price of $0.83, a market capitalization of $8.93 million and a weak Financial Health Score, while the company plans to continue developing its pancreatic screening offering and to evaluate other assets. » More on de.investing.com

Financials

In the last quarter, Mainz Biomed B.V. had revenue of €0 and net profit of -€9.65M

(EUR)	June 2026	YoY
Revenue	0	100.00%
Gross profit	0	100.00%
Net profit	-9.65M	240.50%
EBITDA	-4.91M	14.61%

Fundamentals

Metric	Value
Market capitalization	€26.75M
Number of shares	22.77M
52-week high/low	€4.34 - €0.27
Dividends	No
Beta	2.37
P/E ratio	-0.71
PEG ratio	0.01
P/B ratio	1.27
P/S ratio	120.04

Company profile

Mainz Biomed B.V., ein molekulargenetisches Krebsdiagnoseunternehmen, entwickelt In-vitro-Diagnosetests (IVD) und reine Forschungstests für die klinische Diagnostik in der Humangenetik. Das Unternehmen bietet ColoAlert, einen Screening-Test für Darmkrebs, PancAlert, einen Produktkandidaten für einen Screening-Test für Bauchspeicheldrüsenkrebs, GenoStrip zum Nachweis von Krankheitserregern in der Umwelt auf molekulargenetischer Basis sowie IVD-Tests für Forschungszwecke an. Das Unternehmen wurde 2008 gegründet und hat seinen Sitz in Mainz, Deutschland.

Name	Mainz Biomed B.V.
CEO	David Elliot Lazar
Headquarters	Mainz, Germany
Website	mainzbiomed.com
Sector	Health Care
Industry	Biotechnology
IPO	11/05/2021
Employees	13